国家医保局与人力资源和社会保障部于2025年11月14日联合发布《国家基本医疗保险、生育保险和工伤保险药品目录(2026年)》及《商业健康保险创新药品目录(2026年)》1。这是国家医保局成立以来进行的第9次目录调整,本次调整共新增107种药品,其中51个为1类创新药,占比接近半数,创下历史新高1。与此同时,目录将34种临床价值有限等药品调出1。
新版目录纳入多个具有首创意义的药物,旨在支持源头创新并兼顾民生急需1。关键案例包括普乐司兰钠(全球首个靶向APOC3 mRNA的siRNA药物)、度普利尤单抗(全球首个靶向IL-4Rα生物制剂)、利生奇珠单抗(全球首个获批克罗恩病和溃疡性结肠炎双适应症的IL-23抑制剂)、匹康奇拜单抗(信达生物自主研发的首个国产IL-23p19单抗)以及呫诺美林曲司氯铵胶囊(70年来全球首款全新机制抗精神病药)1。这些药物涵盖心血管、精神疾病及肿瘤等多个治疗领域1。
为确保创新药顺利进入医疗机构使用,四部门印发《关于进一步做好创新药安全合理配备使用工作的通知》,明确两目录内的1类新药不计入“一品两规”,且不纳入公立医疗机构绩效监测指标1。新版目录将于2027年1月1日正式落地执行1。各地医保定点医疗机构原则上应于2027年2月底前召开药事会,调整药品配备1。
China’s National Healthcare Security Administration and the Ministry of Human Resources and Social Security jointly released the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Catalog (2026)" and the "Commercial Health Insurance Innovative Drug Catalog (2026)" 1. This adjustment marks the ninth revision of the national drug list since the administration’s establishment and introduces 107 new medications to the coverage 1. Notably, 51 of these additions are Class 1 innovative drugs, accounting for nearly half of the new entries and representing a historic high for the proportion of such therapies included in the national formulary 1. To optimize resource allocation, 34 drugs deemed to have limited clinical value were removed from the existing list 1. The updated directories are scheduled to take effect on January 1, 2027 1.
The newly approved drugs include several "world-first" therapies designed to fill critical gaps in treatment across cardiovascular diseases, mental health disorders, oncology, and autoimmune conditions 1. Among them is Plecoran sodium, recognized as the first global siRNA drug targeting APOC3 mRNA, and Dupilumab, the world’s first biologic agent targeting IL-4Rα 1. Also included is Risankizumab, the first globally approved IL-23 inhibitor with dual indications for Crohn's disease and ulcerative colitis, alongside Piconquizumab, which is Innovent Biologics’ first domestically developed IL-23p19 monoclonal antibody 1. Additionally, Xanomeline/Trospium Chloride capsules were added, marking the first antipsychotic drug with a novel mechanism in the past 70 years 1.
To facilitate the rapid adoption of these innovative treatments in healthcare settings, four government departments issued a notification this week outlining policies to remove institutional barriers 1. Under the new guidelines, Class 1 innovative drugs listed in both catalogs will not count toward the "two specifications per item" restriction and will be excluded from public hospital performance monitoring metrics 1. Medical institutions designated by local healthcare security bureaus are required to hold pharmacy committee meetings to adjust their drug inventories accordingly by the end of February 2027 1.
评论
还没有评论,欢迎留下第一条。